TIR-199

Syrbactin proteasome inhibitor

Also Known As:

Butanamide, 2-(((dodecylamino)carbonyl)amino)-3-methyl-N-((3E,5S,8S,9E)-5-methyl-2,7-dioxo-1,6-diazacyclododeca-3,9-dien-8-yl)-, (2S)-; N2-(Dodecylcarbamoyl)-N-((3E,5S,8S,9E)-5-methyl-2,7-dioxo-1,6-diazacyclododeca-3,9-dien-8-yl)-L-valinamide

Networked: 3 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Pirrung, Michael C: 3 articles (01/2022 - 04/2016)
2.	Bachmann, André S: 2 articles (01/2020 - 04/2016)
3.	Ibarra-Rivera, Tannya R: 2 articles (01/2020 - 04/2016)
4.	Banerjee, Sourav: 1 article (01/2022)
5.	Chen, Albert: 1 article (01/2022)
6.	Patel, Hitendra M: 1 article (01/2022)
7.	Sah, Robert L: 1 article (01/2022)
8.	Tandon, Vasudha: 1 article (01/2022)
9.	Vala, Ruturajsinh M: 1 article (01/2022)
10.	Dolloff, Nathan G: 1 article (01/2020)

Related Diseases

1.	Neoplasms (Cancer) 04/15/2016 - "In vivo studies in mice revealed a maximum tolerated dose of TIR-199 at 25 mg/kg. The anti-tumor activity of TIR-199 was confirmed in hollow fiber assays in mice. " 01/01/2020 - "Importantly, TIR-199 reduced the tumor burden in a MM mouse model (p < 0.01) confirming its potency in vivo. " 04/15/2016 - "Syrbactin Structural Analog TIR-199 Blocks Proteasome Activity and Induces Tumor Cell Death." 04/15/2016 - "Taken together, the results suggest that TIR-199 is a potent new proteasome inhibitor with promise for further development into a clinical drug for the treatment of multiple myeloma and other forms of cancer. " 04/15/2016 - "In vitro and cell culture-based proteasome activity measurements confirmed that TIR-199 inhibits the proteasome in a dose-dependent manner and induces tumor cell death in multiple myeloma and neuroblastoma cells as well as other cancer types in the NCI-60 cell panel. "
2.	Multiple Myeloma 01/01/2022 - "We report that TIR-199 is a potent constitutive and immunoproteasome inhibitor, capable of inducing cell death in multiple myeloma, triple-negative breast cancer, (TNBC) and non-small cell lung cancer lines. " 04/15/2016 - "Taken together, the results suggest that TIR-199 is a potent new proteasome inhibitor with promise for further development into a clinical drug for the treatment of multiple myeloma and other forms of cancer. " 04/15/2016 - "In vitro and cell culture-based proteasome activity measurements confirmed that TIR-199 inhibits the proteasome in a dose-dependent manner and induces tumor cell death in multiple myeloma and neuroblastoma cells as well as other cancer types in the NCI-60 cell panel. " 01/01/2020 - "Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo."
3.	Triple Negative Breast Neoplasms 01/01/2022 - "We report that TIR-199 is a potent constitutive and immunoproteasome inhibitor, capable of inducing cell death in multiple myeloma, triple-negative breast cancer, (TNBC) and non-small cell lung cancer lines. "
4.	Neuroblastoma 04/15/2016 - "In vitro and cell culture-based proteasome activity measurements confirmed that TIR-199 inhibits the proteasome in a dose-dependent manner and induces tumor cell death in multiple myeloma and neuroblastoma cells as well as other cancer types in the NCI-60 cell panel. "
5.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/01/2022 - "We report that TIR-199 is a potent constitutive and immunoproteasome inhibitor, capable of inducing cell death in multiple myeloma, triple-negative breast cancer, (TNBC) and non-small cell lung cancer lines. "

Related Drugs and Biologics

1.	Proteasome Inhibitors
2.	Proteasome Endopeptidase Complex (Proteasome)
3.	Bortezomib (Velcade)